Table 1.

Prioritization algorithm for biomarker-based targeted treatment

Group	Criterion
1	Biomarker with approved biomarker specific treatment in glioblastoma + with strong survival benefit − with moderate survival benefit or inconsistent
2A	Biomarker with approved biomarker specific treatment in another cancer indication with compelling clinical evidence in glioblastoma
2B	Biomarker with approved biomarker specific treatment in another cancer indication not tested in glioblastoma in a clinical setting
3A	Clinical evidence in glioblastoma, but not approved in glioblastoma or any other cancer indication + mutation − amp/ expression
3B	Clinical evidence in another cancer indication, makes biological sense in glioblastoma, but no clinical evidence in glioblastoma + mutation − amp/expression